Study: Primary homeopathic treatment of cancer of the pancreas, the stomach, the gallbladder and the liver

Reference

CHATTERJE A, BISWAS J, CHATTERJEE AK, BHATTACHARYA S, Mukhopadhyay B and Mandal S. Psorinum therapy in the treatment of gastrointestinal, gallbladder, pancreatic and liver cancer: a prospective clinical study. Evid Based Complement Alternat Med. 2011; 2011: 724743.

Design

not randomized, one-armed observation study on psorinum therapy for the treatment of advanced pancreatic adenocarcinoma, gastrointestinal adenocarcinoma, gallbladder ado carcinoma and hepato cellular carcinoma

participant

A total of 158 subjects (44 with pancreatic adenocarcinoma, 42 with gastrointestinal care carcinoma, 40 with gallbladder ado carcinoma and 32 with hepatocellular carcinoma); In 25 %, a disease in stage III and 71 % of a disease in stage IV was diagnosed.

Cleaning criteria:

1. Histopathological/cytopathological confirmation of malignancy,
2. inoperable tumors and
3. no previous chemotherapy or radiation.

treatment

psorinum D6 was given orally (as liquid drops under the tongue) once a day. Conventional (e.g. infection and pain control, electrolyte compensation, abdominal/pleura parazism) and homeopathic (ie administration of homeopathic medicines in pathological indications) were also given.

The results of this study, which show a 19 to 38-fold improvement in the five-year survival rate in the case of unresolved pancreatic cancer compared to conventional treatment, are fascinating.

target parameter

primary endpoints were the radiological response of the tumor and the survival after 1, 2, 3, 4 and 5 years. Secondary end point was the assessment of the side effects of psorinum 6x.

most important knowledge

in 33.33 % of patients with diagnosed disease in stage III and 10.71 % of patients in stage IV there was a complete tumor reaction. A partial remission occurred at 41.03 % or 33.93 %.

The five-year survival rates were 38.64 % (pancreas), 38.1 % (stomach), 37.5 % (gallbladder) and 43.75 % (liver).

no adverse effects of psorinum were observed, although some participants had slight mouth irritation.

clinical implications

The types of cancer considered in this study are among the most stubborn and deadliest malignant diseases. The conventional treatment of these diseases is better, but still only very limited. For example, in the last decade with the use of standard first-line therapy, the mean overall survival time with advanced pancreatic adenocarcinoma from 3–4 months to 5–8 months. About 80 % of all malignant diseases of the pancreas are inoperable at the time of the diagnosis. ^{4 Therefore, the results of this study, which show a 19 to 38-fold improvement of the five-year survival rate in the event of unrealic pancreatic cancer compared to conventional treatment, are fascinating.}

Similar improvements to the survival rates through psorinum therapy have been demonstrated in the other types of cancer.

However, caution is required when interpreting these results. The promising phase II studies are known for disappointing in the phase III study. Before an unrestricted recommendation can be made, independent verification is required in a controlled context.

In view of the very poor response of these types of cancer, however, it seems sensible that clinicians with oncological experience could offer their patients on an individual basis.

common homeopathic medicines such as Lycopodium C 200 and Baryta Carbonicum C 200 were used supportive and prescribed on a pathological (non -individualized) basis. This is an important feature, since the complexity of the individualized homeopathic prescription is an obstacle to both their reproducibility in independent studies and for their broad clinical acceptance.

The author is currently working on a manuscript that describes the guidelines of the supportive homeopathic measures in detail. In addition, he will publish three detailed case reports on psorinum therapy that provide further insights into the homeopathic support. Therefore, the implementation of this protocol for practitioners should be feasible in the near future.

The primary limiting factor of this study is the lack of control for the effect of supportive homeopathic measures. Since supporting homeopathic medicines have been used to a large extent, it is quite possible that the results are partially (or mainly) due to their influence.

A phase III study currently runs in the psorinum 6x plus conventional and homeopathic supporting treatment with 1) conventional treatment and 2) Psorinum 6x plus conventional (but not homeopathic) Supporting treatment in the treatment of advanced pancreatic cancer is compared.

For further research on integrative oncology, click here here.